PL4031110T3 - Postacie dawkowania inhibitorów tyk2 - Google Patents

Postacie dawkowania inhibitorów tyk2

Info

Publication number
PL4031110T3
PL4031110T3 PL20781719.8T PL20781719T PL4031110T3 PL 4031110 T3 PL4031110 T3 PL 4031110T3 PL 20781719 T PL20781719 T PL 20781719T PL 4031110 T3 PL4031110 T3 PL 4031110T3
Authority
PL
Poland
Prior art keywords
dosage forms
inhibitor dosage
tyk2 inhibitor
tyk2
forms
Prior art date
Application number
PL20781719.8T
Other languages
English (en)
Inventor
Sherif Ibrahim Farag Badawy
Jonathan R. Brown
Candice Y. Choi
Christoph Gesenberg
Vivienne GRAY
John Wynne JONES
Umesh KESTUR
Balvinder S. Vig
Xiaotian S. Yin
Christopher A. ZORDAN
Corey Bloom
Ian Yates
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL4031110T3 publication Critical patent/PL4031110T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL20781719.8T 2019-09-18 2020-09-18 Postacie dawkowania inhibitorów tyk2 PL4031110T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902218P 2019-09-18 2019-09-18
PCT/US2020/051342 WO2021055652A1 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors

Publications (1)

Publication Number Publication Date
PL4031110T3 true PL4031110T3 (pl) 2026-03-30

Family

ID=72670853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20781719.8T PL4031110T3 (pl) 2019-09-18 2020-09-18 Postacie dawkowania inhibitorów tyk2

Country Status (20)

Country Link
US (4) US20230255964A1 (pl)
EP (3) EP4031109B1 (pl)
JP (3) JP7719770B2 (pl)
KR (2) KR20220066310A (pl)
CN (8) CN114727948A (pl)
AU (2) AU2020348783B2 (pl)
BR (2) BR112022004216A2 (pl)
CA (2) CA3151369A1 (pl)
DK (1) DK4031110T3 (pl)
ES (1) ES3060149T3 (pl)
FI (1) FI4031110T3 (pl)
HR (1) HRP20260058T1 (pl)
IL (2) IL291452A (pl)
LT (1) LT4031110T (pl)
MX (4) MX2022003150A (pl)
PL (1) PL4031110T3 (pl)
PT (1) PT4031110T (pl)
RS (1) RS67803B1 (pl)
SI (1) SI4031110T1 (pl)
WO (2) WO2021055652A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020348783B2 (en) * 2019-09-18 2026-04-16 Bristol-Myers Squibb Company Extended release dosage forms for Tyk2 inhibitors
EP4213813A1 (en) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
IL311624A (en) 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
KR20240090866A (ko) * 2021-10-28 2024-06-21 브리스톨-마이어스 스큅 컴퍼니 듀크라바시티닙의 국소 제제
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
WO2024176263A1 (en) * 2023-02-22 2024-08-29 Cipla Limited Deucravacitinib amorphous solid dispersions and polymorphs thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US20020015731A1 (en) 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
CN101152158B (zh) 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2013013114A1 (en) 2011-07-21 2013-01-24 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014043208A1 (en) * 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
CN104968334B (zh) * 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
CA2902424A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
HRP20210764T1 (hr) 2017-03-30 2021-07-09 Bristol-Myers Squibb Company Postupak za pripremu 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazin-3-karboksamida
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
AU2020348783B2 (en) * 2019-09-18 2026-04-16 Bristol-Myers Squibb Company Extended release dosage forms for Tyk2 inhibitors
EP4213813A1 (en) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores

Also Published As

Publication number Publication date
CN119745885A (zh) 2025-04-04
JP2025163082A (ja) 2025-10-28
CN114727949A (zh) 2022-07-08
CN119700773A (zh) 2025-03-28
SI4031110T1 (sl) 2026-03-31
CN119700772A (zh) 2025-03-28
CN119424433A (zh) 2025-02-14
MX2022003150A (es) 2022-04-06
JP2022548688A (ja) 2022-11-21
WO2021055652A1 (en) 2021-03-25
EP4031109C0 (en) 2026-02-18
US20220331315A1 (en) 2022-10-20
EP4031110B1 (en) 2025-12-24
BR112022004216A2 (pt) 2022-05-31
WO2021055651A1 (en) 2021-03-25
JP7812785B2 (ja) 2026-02-10
JP2022548687A (ja) 2022-11-21
PT4031110T (pt) 2026-02-03
HRP20260058T1 (hr) 2026-02-27
US20230255964A1 (en) 2023-08-17
IL291453A (en) 2022-05-01
AU2020349524A1 (en) 2022-03-31
LT4031110T (lt) 2026-02-25
BR112022004550A2 (pt) 2022-05-31
EP4031109B1 (en) 2026-02-18
DK4031110T3 (da) 2026-03-23
JP7719770B2 (ja) 2025-08-06
KR20220066310A (ko) 2022-05-24
CN119424434A (zh) 2025-02-14
EP4031109A1 (en) 2022-07-27
MX2025014308A (es) 2026-01-07
CN119424435A (zh) 2025-02-14
US12521390B2 (en) 2026-01-13
KR20220066105A (ko) 2022-05-23
CA3151137A1 (en) 2021-03-25
MX2025014307A (es) 2026-01-07
FI4031110T3 (fi) 2026-03-10
US20260083733A1 (en) 2026-03-26
AU2020348783B2 (en) 2026-04-16
EP4706778A2 (en) 2026-03-11
RS67803B1 (sr) 2026-03-31
EP4031110A1 (en) 2022-07-27
MX2022003146A (es) 2022-04-06
AU2020348783A1 (en) 2022-03-31
CN114727948A (zh) 2022-07-08
CA3151369A1 (en) 2021-03-25
US20260083734A1 (en) 2026-03-26
IL291452A (en) 2022-05-01
ES3060149T3 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
PL4031110T3 (pl) Postacie dawkowania inhibitorów tyk2
DK3999506T3 (da) Parp1-hæmmere
IL282487A (en) Tyk2 inhibitors and uses thereof
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL292642A (en) Ras inhibitors
EP4007756C0 (en) KIF18A INHIBITORS
EP4007752C0 (en) Kif18a inhibitors
IL283639A (en) Kif18a inhibitors
EP4007753C0 (en) Kif18a inhibitors
IL282090A (en) Tyk2 inhibitors and uses thereof
EP4149460C0 (en) THERAPEUTIC SOLID DOSAGE FORMS
IL280593A (en) Pyrrolopyrimidine itk inhibitors
LT3793565T (lt) Mcl-1 inhibitoriai
IL286248A (en) Tyk2 inhibitors and uses thereof
IL284799A (en) Tyk2 inhibitors and uses thereof
DK4051688T3 (da) Cd73-hæmmere
EP3980011C0 (en) SARM1 HIBITORS
DK3956322T3 (da) Jak1-selektiv kinaseinhibitor
EP4003986A4 (en) Inhibitor compounds
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3966209A4 (en) JAK INHIBITORS
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
IL287560A (en) Mrna formulation
DK4058148T5 (da) Doseringsregime for anti-bcma-midler